T-DXd vs Dato-DXd: Differences in Toxicity in Lungs and Eyes with Same Payload, While SG and Trastuzumab Deruxtecan Remain Safe
Trastuzumab deruxtecan ( T-DXd , DS-8201 ) has a clinical incidence of interstitial lung disease (ILD) of approximately 10-15%. The mechanism of occurrence is not due to a single factor, but rather an interaction between target-dependent and non-target-dependent pathways. Firstly, the target-dependent mechanism arises from the low expression levels of HER2 in alveolar epithelial cells … Read more